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Abstract
Background: While platinum-based chemotherapeutic agents are widely used to treat various solid tumors, the
acquired platinum resistance is a major impediment in their successful treatment. Since enhanced DNA repair
capacity is a major factor in conferring cisplatin resistance, targeting of DNA repair pathways is an effective
stratagem for overcoming cisplatin resistance. This study was designed to delineate the role of nucleotide excision
repair (NER), the principal mechanism for the removal of cisplatin-induced DNA intrastrand crosslinks, in cisplatin
resistance and reveal the impact of DNA repair interference on cisplatin sensitivity in human ovarian cancer cells.
Results: We assessed the inherent NER efficiency of multiple matched pairs of cisplatin-sensitive and -resistant
ovarian cancer cell lines and their expression of NER-related factors at mRNA and protein levels. Our results showed
that only the cisplatin-resistant ovarian cancer cell line PEO4 possessed an increased NER capacity compared to its
inherently NER-inefficient parental line PEO1. Several other cisplatin-resistant cell lines, including CP70, CDDP and
2008C13, exhibited a normal and parental cell-comparable NER capacity for removing cisplatin-induced DNA
intrastrand cross-links (Pt-GG). Concomitant gene expression analysis revealed discordance in mRNA and protein
levels of NER factors in various ovarian cancer cell lines and NER proteins level were unrelated to the cisplatin
sensitivity of these cell lines. Although knockdown of NER factors was able to compromise the NER efficiency, it
only caused a minimal effect on cisplatin sensitivity. On the contrary, downregulation of BRCA2, a critical protein
for homologous recombination repair (HRR), significantly enhanced the efficacy of cisplatin in killing ovarian cancer
cell line PEO4.
Conclusion: Our studies indicate that the level of NER factors in ovarian cancer cell lines is neither a determinant
of their NER capacity nor of the sensitivity to cisplatin, and suggest that manipulation of the HRR but not the NER
factor expression provides an effective strategy for sensitizing cisplatin-resistant tumors to platinating agents.
Background
Since the introduction of inorganic platinum (Pt) drug
molecule cisplatin into the clinic, platinum-based
chemotherapy drugs have been in widespread use to
treat various malignant tumors, including ovarian, testi-
cular, head and neck, and lung cancers [1]. It is gener-
ally accepted that the anti-neoplastic activity of cisplatin
results from its binding to DNA in target cells to induce
DNA cross-links. Chemotherapy with cisplatin is initially
effective for most patients. However, the majority even-
tually becomes refractory to platinum treatment and cis-
platin resistance develops, which severely limits the
effective use of platinum-based chemotherapeutic drugs.
Cisplatin forms primarily 1, 2-intrastrand cross-links
between adjacent purines in DNA, e.g. cis-Pt(NH3)2d
(GpG) (Pt-GG), with Pt bound to two adjacent guanines,
and cis-Pt(NH3)2d(ApG) (Pt-AG), in which the Pt is
bound to adenine and an adjacent guanine. These
lesions contribute to 90% of total damage introduced by
cisplatin. Other DNA damage introduced by cisplatin
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strand cross-links (1-2%) [2]. The cisplatin-induced
intrastrand cross-links are mainly removed by nucleotide
excision repair (NER). Thus, alteration of this DNA
repair pathway is believed to confer resistance to plati-
num-based chemotherapy. The minor 1, 3-intrastrand
cross-links are repaired more efficiently than 1, 2-
intrastrand adducts, due to greater helical distortion
introduced by this bulky adduct [3] and presumed
shielding of 1, 2-intrastrand adducts from its binding to
high-mobility group (HMG) proteins [4,5]. However, the
repair of interstrand cross-links induced by cisplatin is
more complex, and involves excision repair and homo-
logous recombination (HR) [6].
In terms of lesion recognition, NER is the most versa-
tile choice among all repair systems operational in living
cells. This DNA repair system can eliminate a wide vari-
ety of helix-distorting lesions, e.g., UV-induced photole-
sions, Benzo[a]pyrene Diol Epoxide (BPDE) and
cisplatin-induced bulky adducts. The complete NER
reaction involves several biochemical steps including
damage recognition, dual incision, and gap-filling DNA
synthesis [7]. In human cells, the minimal set of NER
components involved in performing repair reaction
comprises XPA, XPC-hHR23B, XPG, RPA, ERCC1-XPF,
TFIIH, PCNA, DNA polymerase δ or ε, and DNA ligase
I [8]. It is becoming increasingly clear and acceptable
that in mammalian cells, NER is mediated by the
sequential assembly of repair proteins at the site of
the DNA lesion [9-11]. HR is a conserved pathway for
the repair of double-strand breaks (DSBs), with Rad51
recombinase playing a central role. BRCA2 is essential
for efficient HR through conjunction with Rad51 [12].
BRCA2-deficient cancer cells are hypersensitive to
DNA-crosslinking agents including cisplatin [13], as a
consequence, women with BRCA1/2-mutated ovarian
carcinoma have a better diagnosis than those without
BRCA1/2- mutation if they receive platinum-based
therapy [14].
Evidence for increased repair of platinum-induced
DNA damage in resistant ovarian cancer cells has been
demonstrated by many groups (see review [15]). How-
ever, most studies focused on the relationship between
total DNA repair capacity and cisplatin resistance, as
DNA repair efficiency was assessed by comparing total
platinum-DNA adduct levels using atomic absorption
spectrometry [16-18], or by examining unscheduled
DNA synthesis (UDS)[19], or by determining reactiva-
tion of cisplatin-damaged plasmid DNA [18]. Since
more than 90% of DNA damage induced by cisplatin is
removed by NER, the relationship between NER and cis-
platin resistance seems especially important. In addition,
the results of correlation between cisplatin resistance
with elevated levels of genes and proteins of the NER
pathway are also contradictory [15]. In this study, we
assessed the NER capacity of multiple pairs of cisplatin-
sensitive and -resistant ovarian cancer cell lines and ana-
lyzed the expression of various NER factors at both
mRNA and protein levels. Our data, indicating that high
NER efficiency to remove cisplatin-induced DNA intras-
trand cross-links does not always correlate to cisplatin
resistance in ovarian cancer cell lines. Manipulation of
HRR, but not NER factor expression, could enhance the
sensitivity of cisplatin-resistant tumors to platinating
agents, providing an important clinically relevant gui-
dance about the potential manipulation of DNA repair
pathways for sensitizing cisplatin-resistant tumors to
platinating agents.
Materials and methods
Cell culture and treatment
The experiments were performed with three different
groups of human ovarian cancer cell lines, each group
having one cisplatin-sensitive parental cell line and one
or two cisplatin-resistant variants (Table 1). The human
ovarian cancer cell line A2780 and its resistant subline
CP70 were kindly provided by Dr. Paul Modrich (Duke
University). Another A2780-derivative resistant subline
C D D Pw a sk i n d l yp r o v i d e db yD r .K a r u p p a i y a hS e l v e n -
diran and Dr. Periannan Kuppusamy (The Ohio State
University). Ovarian cancer cell line 2008 and its resistant
cell line 2008C13 were kindly provided by Dr. Francois
X. Claret (University of Texas - M. D. Anderson Cancer
Center). The A2780-derivative and 2008-derivative cis-
platin-resistant cell lines were produced by intermittent,
incremental exposure of the sensitive parental cell line to
various concentrations of cisplatin. Cisplatin-sensitive
ovarian cancer cell line PEO1 and -resistant PEO4, estab-
lished from the same patient before treatment and after
developing resistance to platinum-based chemotherapy,
were kindly provided by Dr. Thomas C. Hamilton (Fox
Chase Cancer Center). CP70 cells with overexpression of
Table 1 Cisplatin sensitivity and NER capacity of human
ovarian cancer cell lines
Cell line IC50 (μM)
1 NER capacity to
remove Pt-GG
2
A2780 2.97 ± 0.18 ++
CP70 45.78 ± 0.10 ++
CDDP 29.19 ± 9.43 ++
2008 10.82 ± 0.16 ++
2008C13 54.14 ± 0.82 ++
PEO1 12.79 ± 1.15 -
PEO4 44.46 ± 4.76 ++
1IC50 was determined after 1 h treatment with increasing concentrations of
cisplatin. Cell survival was determined by methylene blue staining as
described in the Methods.
2NER capacity was assessed by determining the removal rate of DNA lesions
in cells following various culture times.
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Page 2 of 12DDB2 (CP70-DDB2) were established in our lab [20]. All
cell lines were maintained in RPMI 1640 supplemented
with 10% fetal bovine serum, 100 μg/ml streptomycin
and 100 units/ml penicillin. Cells were grown at 37°C in
humidified atmosphere of 5% CO2 in air. Sensitivity to
cisplatin in these ovarian cancer cell lines following one
hour treatment was assessed by growth inhibition assay
using 96-well plates as described later. The IC50 of each
cell line was shown in Table 1.
For cisplatin treatment, cells were maintained in med-
ium with the desired doses of cisplatin (Sigma, St. Louis,
MO) for 1 h, and then washed with PBS and followed
by incubation in fresh cisplatin-free medium for varying
times post-treatment. For UV exposure, the cultures
were washed with PBS and irradiated with UV at 10 J/
m
2 followed by incubation for varying times. UV-C light
(254 nm) was delivered from a germicidal lamp at a
dose rate of 0.5 J/m
2/s, as measured by a UVX digital
radiometer connected to a UVX-31 sensor (UVP, Inc.,
Upland, CA)
Immunoslot-blot (ISB) analysis
Cells were pre-treated with hydroxyurea (HU) for 24 h
to exclude cells from S phase [21], then UV irradiated
or treated with cisplatin for 1 h, washed twice with
PBS, and further cultured in HU containing medium
for the desired time periods to ensure the inhibition of
DNA replication [22]. The nuclei were isolated and
treated with RNase for 1 h. The genomic DNA was
then isolated with phenol/chloroform/isoamyl alcohol
(25:24:1), precipitated with ethanol, and quantified
using PicoGreen kit assay (Invitrogen, Carlsbad, CA).
The same amounts of denatured DNA were applied to
nitrocellulose membranes. Cisplatin-induced DNA
intrastrand cross-links (Pt-GG) were detected with
anti-Pt-GG antibody [23]. The intensity of each band
was quantified, and the lesion concentrations were
determined from a reference standards run in parallel
to calculate the relative amounts of Pt-GG remaining
at each time point.
Host cell reactivation (HCR) assay
The HCR assay was performed to determine the DNA
repair capacity of individual cell lines. For this study, the
pCMV-Tag 2 expression control plasmid (containing the
firefly luciferase gene, Stratagene, La Jolla, CA) was trea-
ted with cisplatin (1 or 10 μM) to introduce DNA
damage into the plasmid DNA. Both the undamaged
and the damaged pCMV-Tag 2 plasmid were then
transfected into cells (0.5 μg/35-mm dish) using Lipofec-
tamine 2000 transfection reagent (Invitrogen). As an
internal control, the pGL4.73 plasmid (Promega, Madi-
son, WI), which carries a renilla luciferase gene, was
also co-transfected into the cells. The cells were har-
vested 2 days after transfection, and both firefly and
renilla luciferase activities were determined from the
transfected cells using a Dual Luciferase Activity Detec-
tion System (Promega). The activity of firefly luciferase
in each experiment was calculated as relative activity to
the renilla luciferase activity to minimize the experimen-
tal variations. The ratio of luciferase activities in the
same cell line for both undamaged and damaged plas-
mid was used to determine the DNA repair capacity of
the host cells.
Western blotting analysis
Whole cell lysates were prepared by boiling cell pellets
for 10 min in lysis buffer (2% SDS, 10% Glycerol, 62
mM Tris-HCl, pH 6.8 and a complete mini-protease
inhibitor cocktail [Roche Applied Science]). After
protein quantification with Bio-Rad Dc Protein Assay
(Bio-Rad Laboratories, Hercules, CA), equal amounts of
proteins were loaded, separated on a polyacrylamide gel,
and transferred to a nitrocellulose membrane. Protein
bands were immuno-detected with appropriate anti-
bodies, e.g., rabbit anti-XPC and anti-DDB2 antibodies
generated in our laboratory [24], mouse anti-XPA,
mouse anti-XPF, and mouse anti-Tubulin antibodies
purchased from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA). Rabbit anti-XPG antibody purchased from
Bethyl Laboratory (Montgomery, TX). Mouse anti-
BRCA2 (Ab-1) antibody purchased from Calbiochem
(Gibbstown, NJ).
Real-time quantitative RT-PCR
Total RNA was purified from various cell samples using
Trizol (Invitrogen). The cDNA was generated by reverse
transcription using Superscriptase III (Invitrogen) and
oligo (dT) in a 20 μl reaction containing 1 μgo ft o t a l
RNA. An aliquot of 0.5 μl cDNA was used in each 20 μl
PCR reaction, using Applied Biosystem’sP o w e rS Y B R
Green PCR Master Mix and the reactions were run on an
ABI 7500 Fast Real-Time PCR system. The following pri-
mers were used: XPA, forward, 5’- GCA GCC CCA AAG
ATA ATT GA -3’; reverse, 5’-T G GC A AA T CA A A
GTG GTT CA -3’;X P C ,f o r w a r d ,5 ’- GAC AAG CAG
GAG AAG GCA AC -3’;r e v e r s e ,5 ’- GGT TCG GAA
TCC TCA TCA GA -3’;X P F ,f o r w a r d ,5 ’- TGC GTG
AAT TTC GAA GTG AG -3’; reverse, 5’-T G GA G A
TGC ACT GGC TGT AG -3’;X P G ,f o r w a r d ,5 ’- GGG
AAA CCT GAT CTC GAC AA -3’; reverse, 5’-T C A
ATT CGG AGC TGT GTC TG -3’;E R C C 1 ,f o r w a r d ,5 ’-
TTG TCC AGG TGG ATG TGA AA -3’; reverse, 5’-
GCT GGT TTC TGC TCA TAG GC -3’;a n dG A P D H ,
forward, 5’- GAA GGT GAA GGT CGG AGT -3’;
reverse, 5’- GAA GAT GGT GAT GGG ATT TC -3’.
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Cells were seeded in 96-well plates at an initial density
of 2 × 10
3, incubated for 24 h, and treated with increas-
ing doses of cisplatin for 1 h. All test concentrations
were repeated in quadruplicates. After the drug treat-
ment, cultures were incubated for another 72 h. At the
end of the growth period, the cells were washed with
PBS, fixed with 3.7% formaldehyde for 30 min, and
stained with 1.0% methylene blue for 30 min. The plate
was rinsed in running water and then left to dry. 100 μl
solvent (10% acetic acid, 50% methanol and 40% H2O)
was added to each well to dissolve the cells and, optical
density (OD) of the released color was read at 660 nm.
The relative cell survival was calculated with the values
of mock-treated cells set as 100%.
Transfection with siRNAs
siRNA SMARTpools designed to target human XPA,
XPF or XPG were purchased from Dharmacon Inc
(Denver, CO). siRNA directed against BRCA2 (5’-A A C
AAC AAT TAC GAA CCA AAC -3’) [25], and a scram-
ble non-targeting siRNA, were synthesized by Dharma-
con. 50 nM siControl, siXPF or siXPG were separately
transfected into CP70 or CDDP cells using Lipofecta-
mine 2000 transfection reagent (Invitrogen, Carlsbad,
CA) according to the manufacture’s instruction. 100 nM
siControl, 50 nM siXPA + 50 nM siControl, 50 nM
siBRCA2 + 50 nM siControl, and 50 nM siXPA +
50 nM siBRCA2 were transfected into PEO4 cells,
respectively, using the same transfection procedure as
described above.
HR repair (HRR) measurement by immunofluorescence of
gH2AX
PEO4 cells growing on the coverslips were transfected
with various siRNA as described above for 48 h, irra-
diated at 10 Gy with RS-2000 X-ray Biological Irradia-
tor, and further cultured for 1 or 24 h. Cells were fixed
and permeabilized with 2% paraformaldehyde in 0.5%
Triton X-100, and stained with mouse anti-gH2AX anti-
body, and anti-mouse IgG conjugated with Texas Red.
Fluorescence images were obtained with a Nikon fluor-
escence microscope E80i (Nikon, Tokyo, Japan). The
digital images were then captured with a cooled CCD
camera and processed with the help of its SPOT soft-
ware (Diagnostic Instruments, Sterling Heights, MI).
Results
Determination of cisplatin dose to induce equivalent
Pt-GG in paired cisplatin-sensitive and -resistant ovarian
cancer cell lines
One of the well known mechanisms of the cisplatin
resistance is reduced drug intracellular uptake, which
can result in lesser DNA damage and reduced
cytotoxicity [26]. Thus, in order to study the changes
of DNA repair capacity, it is essential to induce
equivalent amounts of initial DNA lesions in different
cell lines. To find the cisplatin doses that cause equiva-
lent Pt-GG level in several pairs of cisplatin-sensitive
and -resistant ovarian cancer cell lines A2780/CP70,
A2780/CDDP, 2008/2008C13, and PEO1/PEO4, we
quantitated the amount of Pt-GG in these cell lines
after 1 h treatment with various doses of cisplatin. As
s h o w ni nF i g u r e1 ,i nc o m p a r i s o nw i t ht h ep a r e n t a l
cisplatin-sensitive cancer cell lines A2780, 2008 and
PEO1, their corresponding derivative resistant cell
lines CP70, CDDP, 2008C13, and PEO4 exhibit a lower
production of Pt-GG following the treatment with cis-
platin at the same doses. For example, the amount of
Pt-GG induced by 10 μM of cisplatin in A2780 cells is
equivalent to that induced by 40 μM of cisplatin in
CP70 and CDDP cells. The amount of Pt-GG pro-
duced by 7.5 μM of cisplatin in 2008 cells is equivalent
to that produced by 40 μM of cisplatin in 2008C13
cells, and the amount of Pt-GG induced by 15 μMo f
cisplatin in PEO1 cells is equivalent to that induced by
20 μM of cisplatin in PEO4 cells. Therefore, in subse-
quent experiments, we used the different doses of cis-
platin to treat different cell lines to ensure that the
same initial amount of Pt-GG was produced when
assessing the NER capacity in this study.
NER efficiency of various cisplatin-sensitive and resistant
ovarian cancer cell lines
It is believed that increased DNA repair efficiency is
one of the reasons for the development of cisplatin
resistance. To validate the contribution of NER path-
way to the development of cisplatin resistance, we spe-
cifically detected and compared the removal rate of
cisplatin-induced 1,2-intrastrand crosslinks (Pt-GG)
between multiple matched pairs of cisplatin-sensitive
and -resistant ovarian cancer cell lines by using
immuno-slot blot assay with anti-Pt-GG antibody. Sur-
prisingly, we did not observe any significant difference
in the removal of Pt-GG between A2780 and CP70,
A2780 and CDDP, as well as 2008 and 2008C13 cells
(Figure 2A-F). On the other hand, however, the NER
capacity of cisplatin-resistant PEO4 was significantly
higher than that of cisplatin-sensitive PEO1 cells
(Figure 2G & 2H). We then assessed the NER capacity
by an alternate assay based on host cell reactivation.
As shown in Figure 3A & 3B, when cisplatin-damaged
pCMV-Tag 2 plasmids were transfected into various
ovarian cancer cell lines for 48 h, the relative luciferase
activities in A2780 and CP70 cell lines were compar-
able, while PEO4 cells exhibited significantly higher
relative luciferase activity than PEO1 cells, indicating
that A2780 and CP70 cell lines have similar DNA
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Figure 2 NER efficiency of various cisplatin-sensitive and -resistant ovarian cancer cell lines determined by ISB. A2780 and CP70 (A, B),
A2780 and CDDP (C, D), 2008 and 2008C13 (E, F), PEO1 and PEO4 (G, H) cells were pre-treated with HU for 24 h, then treated with various
concentration of cisplatin for 1 h (A2780: 10 μM; CP70: 40 μM; CDDP: 40 μM; 2008: 7.5 μM; 2008C13: 40 μM; PEO1: 15 μM; PEO4: 20 μM), and further
cultured in HU containing medium for the indicated time periods. Total DNA was isolated and analyzed by ISB assay for cisplatin-induced
intrastrand cross-links with anti-Pt-GG antibody. The intensity of each band was quantified by scanning images and processing with Alphaimager-
2000 software. The relative percentage of remaining Pt-GG at different time points is an average of three independent repeats. (n = 3, Bar: SD).
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Page 5 of 12repair capacity in removing cisplatin-induced DNA
lesions, whereas PEO4 cells have higher DNA repair
capacity than PEO1 cells. In addition, ISB assay indi-
cated that about 60% Pt-GG was removed after 24 h in
PEO4 cells (Figure 2G &2H), a rate similar to that of
other ovarian cancer cell lines, e.g., A2780, CP70,
CDDP, 2008 and 2008C13 (Figure 2A-F), indicating
that this cell line has normal NER capacity. However,
severe impairment of NER capacity of PEO1 cells is
evident by the lack of Pt-GG removal even at 24 h
post-treatment (Figure 2G &2H). These data indicate
that NER capacity is not increased in the acquired cis-
platin-resistant ovarian cancer cell lines derived from
cancer cells that already have high NER efficiency. In
contrast, if the cisplatin-sensitive cells have a deficient
NER, its derivative resistant cells may display enhanced
NER efficiency (Table 1).
Expression of NER factors in various cisplatin-sensitive
and -resistant ovarian cancer cell lines
The complete processing by NER involves several
biochemical steps including damage recognition, dual
incision, and gap-filling DNA synthesis [7]. In human
cells, the minimal set of NER components involved in
the first two steps comprises XPA, RPA, TFIIH, XPC-
hHR23B, XPF-ERCC1, and XPG. In order to understand
the relationship between the expression of these NER
factors and the possibility of developing cisplatin resis-
tance, we evaluated the status of mRNA and protein
levels of XPA, XPC, XPF, XPG, ERCC1, and DDB2 in
various cisplatin-sensitive and -resistant ovarian cancer
cell lines. As shown in Figure 4A, A2780 cell line exhi-
bits higher mRNA levels of all NER factors tested in
this study compared with cisplatin-resistant cell lines
derived from A2780 cell line. However, the protein
expression levels of these factors are not consistent with
the mRNA levels. As shown in Figure 4B, in compari-
son with the parental A2780 cells, CP70 cells have
higher protein level of XPA, but lower level of XPC and
XPG, while CDDP cells exhibit higher protein level of
XPA and XPG, but lower level of XPC, XPF and
ERCC1. In addition, 2008 cell line exhibit lower mRNA
level for XPC, XPF and ERCC1 compared with its deri-
vative 2008C13 cell line (Figure 4C). However, the pro-
tein level of XPF in 2008 cell line is higher than that in
2008C13 (Figure 4D). Furthermore, the mRNA of all
NER factors determined in PEO4 cells displayed higher
levels than in PEO1 cells (Figure 4E), but the protein
levels of XPF and XPA in PEO4 cells are lower than in
PEO1 cells (Figure 4F). These data indicate that mRNA
level does not always reflect the corresponding protein
level of NER factors within cells. Furthermore, the fact
that derivative A2780 and 2008 cisplatin-resistant can-
cer cell lines exhibit normal NER capacity to remove
Pt-GG, indicates that low level of certain NER proteins
(e.g., XPC and XPG in CP70 cell line, XPC, XPF, and
ERCC1 in CDDP cell line, XPF in 2008C13 cell line)
may not result in the low NER capacity. Similarly,
although PEO4 cells have lower level of XPA and XPF
proteins, their NER capacity is higher than PEO1 cells.
Thus, the amount of NER factors, by itself, cannot be
considered a determinant of NER efficiency and cispla-
tin sensitivity.
To further address the question regarding the contri-
bution of the level of NER factors to NER capacity and
cisplatin sensitivity, we knocked down the individual
expression of either XPF or XPG in both CP70 and
Table 1 Cisplatin sensitivity and NER capacity of human
ovarian cancer cell lines
Cell line IC50 (μM)
1 NER capacity to
remove Pt-GG
2
A2780 2.97 ± 0.18 ++
CP70 45.78 ± 0.10 ++
CDDP 29.19 ± 9.43 ++
2008 10.82 ± 0.16 ++
2008C13 54.14 ± 0.82 ++
PEO1 12.79 ± 1.15 -
PEO4 44.46 ± 4.76 ++
1IC50 was determined after 1 h treatment with increasing concentrations of
cisplatin. Cell survival was determined by methylene blue staining as
described in the Methods.
2NER capacity was assessed by determining the removal rate of DNA lesions
in cells following various culture times.
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Figure 3 DNA repair capacity of various cisplatin-sensitive and
-resistant ovarian cancer cell lines determined by HCR. A2780
and CP70 cells (A), PEO1 and PEO4 cells (B) were transfected with
cisplatin-damaged and undamaged pCMV-Tag 2 plasmid. As an
internal control, the pGL4.73 plasmid, which carries a renilla
luciferase gene, was co-transfected with the pCMV-Tag 2 plasmid.
The cells were harvested 2 days after transfection, both firefly and
renilla luciferase activities were determined. The activity of firefly
luciferase in each experiment was calculated as relative activity to
the renilla luciferase activity to minimize the experimental variations.
The ratio of luciferase activities in the same cell line for both
undamaged and damaged plasmid was used to determine the DNA
repair ability of the host cells. The relative luciferase activity is an
average of three independent repeats. Bars represent standard
deviation (SD).
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Page 6 of 12CDDP cells using their corresponding siRNA, and
examined their NER capacity to remove Pt-GG and
their sensitivity to cisplatin. As shown in Figure 5A
&5B, both XPF and XPG siRNA quantitatively knocked
down their corresponding target protein expression by
greater than 90% in both CP70 and CDDP cell lines.
The knockdown of XPG further reduced the NER capa-
city only slightly in both CP70 and CDDP cells (Figure
5C, D), and sensitized both CP70 and CDDP cell lines
to cisplatin, once again by only a slight extent with IC50
of 34.1 μM vs 49.2 μM in CP70 cells and 18.2 μM vs
32.4 μM in CDDP cells (Figure 5E, F). In contrast,
knockdown of XPF significantly inhibited the NER capa-
city in both CP70 and CDDP cell lines (Figure 5C, D),
while having a lesser influence on their sensitivity to cis-
platin, i.e., IC50 of 38.2 μM vs 49.2 μM in CP70 cells
and 25.7 μM vs 32.4 μM in CDDP cells (Figure 5E, F).
This data clearly indicates that the level of NER factors
may not have a direct correlation with the sensitivity to
cisplatin in ovarian cancer cell lines.
Downregulation of HRR factor BRCA2, but not NER factor
XPA, sensitizes PEO4 cells to cisplatin
Downregulation of DNA repair pathways is believed to
be one of the useful strategies for sensitizing cancer
cells to cisplatin [27]. Since cisplatin-induced intrastrand
crosslinks are mainly removed by NER, while the inter-
strand crosslinks are removed by HRR, we compared
the effects of inhibiting NER and HRR pathways on the
cisplatin sensitivity of PEO4 cells by knocking down a
critical NER factor XPA, or a critical HRR factor
BRCA2. Figure 6A showed that siXPA and siBRCA2 can
downregulate their corresponding proteins significantly
in PEO4 cells. We then analyzed the functional conse-
quence of XPA and BRCA2 knockdown in PEO4 cells.
As indicated by Figure 6B, knockdown of XPA, but not
BRCA2, compromised the NER capacity, as reflected by
more Pt-GG remaining in siXPA transfected cells. In
contrast, knockdown of BRCA2, but not XPA, compro-
mised the HRR capacity, as reflected by the persistence
of gH2AX up to 24 h following IR treatment in
siBRCA2 transfected cells (Figure 6C). As expected,
knockdown of XPA and BRCA2 together inhibited both
NER and HRR efficiency (Figure 6B,C). Finally, we
assessed the sensitivity of PEO4 cells with either XPA
knockdown or BRCA2 knockdown to cisplatin. As
shown in Figure 6D, siXPA transfection did not enhance
PEO4 cells to cisplatin, with an IC50 of 41.0 ± 5.0 μM
vs 45.1 ± 6.6 μM of siControl transfected PEO4 cells.
However, siBRCA2 transfection significantly enhanced
PEO4 cells to cisplatin, with an IC50 of 15.3 ± 1.3 μM.
Double knockdown of XPA and BRCA2 in PEO4 cells
conferred the cisplatin sensitivity comparable to BRCA2
knockdown alone, with an IC50 of 12.7 ± 2.6 μM. These
data indicated that specifically targeting HRR pathway is
more efficient than targeting NER pathway in overcom-
ing cisplatin resistance of ovarian cancers.
Discussion
Repair of different cisplatin induced DNA lesions
Cisplatin can induce both intrastrand and interstrand
crosslinks in living cells with former accounting for
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Page 9 of 12more than 90% of the total DNA damage. Intrastrand
crosslinks, the most abundant lesion, can be removed
through NER pathway, while interstrand crosslinks are
removed through a complex mechanism involving
cooperation of several DNA repair pathways, i.e., NER,
homologous recombination (HR) and translesion
synthesis (TLS) (reviewed in [2]). Since cisplatin-
induced DNA damage is the main inducer of apoptosis
and contributes to the anti-tumor activity of cisplatin,
enhanced DNA repair is believed to be one of the
major mechanisms of cisplatin resistance [reviewed in
[26]] as it enables tumor cells to overcome cisplatin
toxicity. From this standpoint, relationship between
DNA repair capacity and cisplatin resistance has been
extensively studied [see review [28]], but the basis of
contribution of NER to cisplatin resistance remains
unsettled. Several groups have compared the NER effi-
ciency between cisplatin-sensitive and -resistant cancer
cell lines by detecting the removal rate of cisplatin-
induced intrastrand crosslinks in vivo or in vitro,a n d
suggested that NER efficiency is enhanced in cisplatin-
resistant cancer cell lines [29], and an intervention of
NER pathway may be utilized for improving the effi-
cacy of cisplatin treatment [29-31]. A recent study,
however, raised a concern about the key role of NER
pathway in determining cisplatin resistance. There is
evidence that a defect in the interaction between
ERCC1 and XPA, that disrupts NER, has no major
effect on the cellular sensitivity to cisplatin [32]. In
addition, Usanova et al [33] have just recently reported
that the repair of intrastrand crosslinks is similar in
cisplatin sensitive testis tumor cells and resistant blad-
der cancer cells. Our comprehensive experimentation
has now shown that cisplatin-resistant cell lines
derived from A2780 and 2008 ovarian carcinoma cell
lines do not exhibit any significant enhancement of
NER capacity as compared to their parent cell lines
and only PEO1-derived cisplatin-resistant ovarian
cancer cell line, PEO4, has higher NER capacity than
its parental cell line. Considering A2780 and 2008 cell
lines possess efficient NER capacity, while PEO1 cell
line displays impaired NER function, it seems that
enhanced NER only occurs in the cisplatin-resistant
cells derived from NER-deficient parental cell lines.
It is worth noting that our ISB assay is highly specific
for assessing the removal rate of 1,2-Pt-GG, the most
abundant DNA damage induced by cisplatin. Although,
the efficiency of removal of 1,2-Pt-GG was comparable
between A2780 and CP70/CDDP, or 2008 and 2008C13
cell lines, we cannot rule out the possibility that the
removal of other kinds of cisplatin-induced DNA lesions
is more efficient in cisplatin-resistant ovarian cancer cell
lines than that in sensitive cell lines, which could be
contributing to the cisplatin resistance of CP70 cell line
[18]. For example, it has been reported that the inter-
strand crosslinks were removed rapidly from highly cis-
platin resistant C80 and C200 cells than their parental
sensitive cells [16,34].
NER factors, repair efficiency, and cisplatin sensitivity
Our thorough evaluation of the NER protein levels
( X P A ,X P C ,X P F ,X P G ,E R C C 1 ,a n dD D B 2 )a n dc o r r e -
sponding mRNA levels in various cisplatin-sensitive and
-resistant ovarian cancer cell lines revealed that the
transcript levels of various NER factors do not accu-
rately reflect their protein levels. This is consistent with
reports that have shown significantly lower levels of
ERCC1, XPF, and XPA protein in testis tumor cell lines
do not cohere with the transcriptional efficiency or
mRNA stability of the cognate factors [35]. Thus, the
transcript level of NER factors detected by quantitative
RT-PCR assay, which is widely used in clinical and epi-
demiological studies, must not be relied as a surrogate
of active cellular protein levels and the capacity for
DNA repair.
Many studies have demonstrated an increased repair
rate in cisplatin-resistant tumor cells [see review [28]].
In addition, overexpression of NER genes has been
correlated with repair and resistance [15]. However,
our studies demonstrated that ovarian cancer cell lines
exhibiting low level of certain NER factors (XPF in
CDDP, XPG in CP70) are still resistant to cisplatin,
indicating the amount of NER proteins may not be a
key determinant of NER efficiency. There are six
essential proteins (or complexes) employed in NER,
i.e., XPC-hHR23B, TFIIH, XPA, RPA, XPG, and XPF-
ERCC1. Lack of any one of these factors can impair
NER efficiency in vivo and in vitro [8]. However, the
threshold level of proteins, required for efficient NER,
may actually be very low. For example, lower amounts
of XPA protein are sufficient to recover UV-resistance
of XP-A cells [36]. In the same vein, XPA must be
reduced to <10% of the normal wild-type levels to ren-
der XPA as a limiting factor for NER and consequently
imparting cellular sensitivity [37]. In our study, the
very low protein level of XPF in CDDP cells and very
low level of XPG protein in CP70 cells did not com-
promise the NER efficiency of these cells, and empha-
size further that the low levels of NER factors are
sufficient to execute efficient NER.
Among the basic NER proteins, ERCC1 is one of the
most extensively studied NER factors. The in vitro,
in vivo, and clinical studies have demonstrated that high
expression of ERCC1 correlates with cisplatin resistance
in multiple tumors [38] while knock-down of ERCC1
expression enhances the cisplatin cytotoxicity in cispla-
tin-resistant ovarian cancer cells [30]. Moreover, patients
with completely resected non-small-cell lung cancer and
Wang et al. Molecular Cancer 2011, 10:24
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Page 10 of 12ERCC1-negative tumors appear to benefit from adjuvant
cisplatin-based chemotherapy, whereas patients with
ERCC1-positive tumors do not [39]. In addition to
being involved in NER of intrastrand crosslinks, ERCC1
is also important in the repair of interstrand crosslinks
through homologous recombination [40,41]. It is
reported that although the excision repair of cisplatin-
induced intrastrand crosslinks in PC3 cells was attenu-
ated to the same extent by XPA and ERCC1 knock-
down, downregulation of ERCC1, but not XPA,
sensitized PC3 prostate cancer cells to cisplatin [42],
indicating the role of ERCC1 in the repair of interstrand
crosslinks may be more important in cisplatin resistance.
Targeting DNA repair pathways to improve the efficacy of
cisplatin towards resistant cancers
DNA repair proteins can be excellent candidate targets
for the development of new therapies to overcome resis-
tance to cancer therapy. Since NER is the major mechan-
ism for removing cisplatin-induced DNA damage, NER
factors are being extensively investigated for realizing this
goal. However, the effect of down-regulation of NER pro-
teins on cisplatin sensitivity has remained contradictory.
For example, it was reported that transfection with anti-
sense XPA RNA could sensitize human lung adenocarci-
noma cells to cisplatin [31], whereas, knocking down
XPA did not increase cisplatin sensitivity in prostate can-
cer cell line, although down-regulation of XPA did inhibit
cisplatin intrastrand crosslinks repair [42]. In addition,
increasing XPA levels in testicular tumor cells by a 10-
fold did not increase resistance to cisplatin [43]. In this
study, we have found that although the protein levels of
XPF and XPG were knocked down more than 90% in cis-
platin-resistant CP70 and CDDP cell lines, and XPA was
also downregulated significantly in PEO4 cells, the NER
efficiency was only inhibited moderately and the sensitiv-
ity to cisplatin was increased only slightly. We speculate
that despite the very low amount of some NER proteins
(not absent) in cancer cells, these levels are sufficient for
NER to remove cisplatin-induced intrastrand crosslinks.
Thus, reducing NER proteins to similar low levels may
not achieve the effective NER inhibition required for
increasing cisplatin sensitivity.
As discussed above, cisplatin forms a variety of
adducts including DNA intrastrand crosslinks and inter-
strand crosslinks. Given the cisplatin-induced DNA
interstrand crosslinks are mainly repaired by HRR [6],
our finding that BRCA2, but not XPA downregulation,
enhanced cisplatin sensitivity in PEO4 cells, indicates
the minor interstrand crosslinks may be more important
than major intrastrand crosslinks to the cell killing,
further suggesting that targeting HRR pathway might be
more efficient than targeting NER pathway in enhancing
the cisplatin sensitivity of ovarian cancer cells [25,32,33].
Conclusion
Our studies indicate that enhanced NER capacity is not
the underlying cause of acquired cisplatin resistance of
ovarian cancer cell lines derived from cells that have
already high NER efficiency. In contrast, if the cispla-
tin-sensitive cells have a deficient NER, its derivative
resistant cells can exhibit enhanced NER efficiency.
Nevertheless, the level of NER factors in ovarian can-
cer cell lines is neither a determinant of their NER
capacity nor of the sensitivity to cisplatin. Interfering
with NER pathway through downregulation of NER
factors is not an effective means of enhancing cisplatin
resistance in ovarian cancer cells. In contrast, the dis-
ruption of HR through downregulation of BRCA2 can
efficiently sensitize the functional BRCA2-containing
cisplatin-resistant ovarian cancer cells to cisplatin
treatment. Overall study suggests that the manipula-
tion of HRR but not NER factor expression can serve
as an effective strategy for sensitizing cisplatin-resistant
tumors to platinating agents.
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